Your browser is no longer supported. Please, upgrade your browser.
Settings
TPVY TriplePoint Venture Growth BDC Corp. daily Stock Chart
TPVY [NYSE]
TriplePoint Venture Growth BDC Corp.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.29%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month0.00%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-0.20%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-0.45%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year1.36%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range22.38 - 26.98 Perf YTD2.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.23% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low14.25% ATR0.13
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)43.16 Volatility0.45% 0.50%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.57 Prev Close25.56
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.96K Price25.57
Recom- SMA20-0.17% SMA50-0.58% SMA200-0.15% Volume4,556 Change0.05%
TriplePoint Venture Growth BDC Corp is a business development company specializing investments in growth stage. It also provides debt financing to venture growth space companies which includes growth capital loans, equipment financings, revolving loans, and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It does not take board seat in the company.